What is William Blair’s Estimate for TARS Q4 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at William Blair lowered their Q4 2025 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 4th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of ($0.05) for the quarter, down from their previous estimate of ($0.04). The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.20 EPS, Q4 2026 earnings at $0.43 EPS and FY2026 earnings at $0.70 EPS.

Several other analysts also recently weighed in on TARS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Wednesday, October 8th. HC Wainwright upped their price target on shares of Tarsus Pharmaceuticals from $72.00 to $88.00 and gave the stock a “neutral” rating in a research note on Monday, October 20th. The Goldman Sachs Group reiterated a “neutral” rating and set a $51.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Thursday. Guggenheim upped their target price on Tarsus Pharmaceuticals from $84.00 to $87.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, September 5th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $69.83.

Tarsus Pharmaceuticals Trading Down 0.2%

NASDAQ:TARS opened at $68.09 on Friday. The business’s 50 day moving average is $62.57 and its two-hundred day moving average is $51.09. Tarsus Pharmaceuticals has a 52 week low of $38.51 and a 52 week high of $76.81. The company has a market cap of $2.87 billion, a PE ratio of -33.71 and a beta of 0.82. The company has a quick ratio of 5.21, a current ratio of 4.29 and a debt-to-equity ratio of 0.22.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.05. The firm had revenue of $118.70 million during the quarter, compared to analyst estimates of $114.22 million. Tarsus Pharmaceuticals had a negative return on equity of 26.29% and a negative net margin of 22.17%.

Insiders Place Their Bets

In related news, CEO Bobak R. Azamian sold 6,000 shares of the company’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $55.37, for a total transaction of $332,220.00. Following the transaction, the chief executive officer directly owned 812,106 shares of the company’s stock, valued at approximately $44,966,309.22. The trade was a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William J. Phd Link sold 27,116 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $57.00, for a total transaction of $1,545,612.00. Following the completion of the sale, the director directly owned 143,332 shares of the company’s stock, valued at $8,169,924. This trade represents a 15.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 39,116 shares of company stock valued at $2,177,832 in the last 90 days. Corporate insiders own 8.97% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Amalgamated Bank lifted its holdings in shares of Tarsus Pharmaceuticals by 30.1% during the 1st quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after buying an additional 295 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Tarsus Pharmaceuticals by 26.4% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,623 shares of the company’s stock valued at $66,000 after acquiring an additional 339 shares in the last quarter. Osaic Holdings Inc. lifted its stake in Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Tarsus Pharmaceuticals by 220.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock worth $164,000 after acquiring an additional 2,782 shares in the last quarter. Finally, Quarry LP increased its stake in shares of Tarsus Pharmaceuticals by 20.0% during the 1st quarter. Quarry LP now owns 3,599 shares of the company’s stock worth $185,000 after purchasing an additional 599 shares during the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.